CO6460752A2 - Respuesta inmunitaria reforzada en especies aviares - Google Patents
Respuesta inmunitaria reforzada en especies aviaresInfo
- Publication number
- CO6460752A2 CO6460752A2 CO11153951A CO11153951A CO6460752A2 CO 6460752 A2 CO6460752 A2 CO 6460752A2 CO 11153951 A CO11153951 A CO 11153951A CO 11153951 A CO11153951 A CO 11153951A CO 6460752 A2 CO6460752 A2 CO 6460752A2
- Authority
- CO
- Colombia
- Prior art keywords
- avian species
- immune response
- procedure
- lipids
- avian
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title abstract 3
- 241000894007 species Species 0.000 title 1
- 241000271566 Aves Species 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 5
- 230000002519 immonomodulatory effect Effects 0.000 abstract 3
- 150000002632 lipids Chemical class 0.000 abstract 3
- 208000035473 Communicable disease Diseases 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 244000144992 flock Species 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000012447 hatching Effects 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000015788 innate immune response Effects 0.000 abstract 1
- 230000009993 protective function Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Objeto de la Invención: Procedimiento para provocar una respuesta inmunitaria no específica de antígeno en las especies aviares que también disminuye la morbididad de una bandada, proporciona una función protectora para más de un agente infeccioso y proporciona protección durante un periodo de tiempo más prolongado que otros procedimientos generalmente conocidos en la técnica.Característica de la Invención.Un procedimiento para provocar una respuesta inmunitaria en al menos un miembro de las especies aviares que comprende administrar al miembro de la especie aviar una cantidad eficaz de una composición inmunomoduladora para provocar una respuesta inmunitaria en el miembro de la especie aviar, en el que la composición inmunomoduladora comprende: a. un vehículo de liberación liposómico catiónico, que comprende lípidos seleccionados del grupo constituido por lípidos en vesículas multilaminares y lípidos extrudidos, y b. una molécula de ácido nucleico, la cual es un vector aislado de ácido nucleico derivado de bacteria sin un inserto génico o un fragmento del mismo.Campo de aplicación.El procedimientos es utilizado para proteger las especies aviares de enfermedades infecciosas y tratar la enfermedad infecciosa de las poblaciones aviares. También permite el uso seguro de vacunas disponibles previamente sólo para la administración tras la eclosión, para su uso in ovo. Además, el procedimiento permite la combinación de más de una vacuna con la composición inmunomoduladora.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17809909P | 2009-05-14 | 2009-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6460752A2 true CO6460752A2 (es) | 2012-06-15 |
Family
ID=42357738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11153951A CO6460752A2 (es) | 2009-05-14 | 2011-11-11 | Respuesta inmunitaria reforzada en especies aviares |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US20120064151A1 (es) |
| EP (2) | EP2992899B1 (es) |
| JP (1) | JP5679589B2 (es) |
| KR (2) | KR101966989B1 (es) |
| CN (2) | CN102427827B (es) |
| AR (1) | AR076767A1 (es) |
| AU (1) | AU2010246652B2 (es) |
| BR (1) | BRPI1010803A2 (es) |
| CA (1) | CA2761736C (es) |
| CL (1) | CL2011002808A1 (es) |
| CO (1) | CO6460752A2 (es) |
| CR (1) | CR20110595A (es) |
| DK (2) | DK2429581T3 (es) |
| EC (1) | ECSP11011448A (es) |
| ES (2) | ES2808827T3 (es) |
| HK (1) | HK1168032A1 (es) |
| HR (2) | HRP20151117T1 (es) |
| HU (2) | HUE025765T2 (es) |
| IL (1) | IL215900A (es) |
| LT (1) | LT2992899T (es) |
| MX (1) | MX336019B (es) |
| MY (1) | MY162561A (es) |
| NI (1) | NI201100196A (es) |
| NZ (1) | NZ596366A (es) |
| PE (1) | PE20120903A1 (es) |
| PL (2) | PL2429581T3 (es) |
| PT (2) | PT2992899T (es) |
| RU (1) | RU2570732C9 (es) |
| SI (2) | SI2992899T1 (es) |
| SV (1) | SV2011004056A (es) |
| TW (1) | TWI555846B (es) |
| UA (1) | UA106076C2 (es) |
| UY (1) | UY32634A (es) |
| WO (1) | WO2010130374A1 (es) |
| ZA (1) | ZA201107827B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2257306B1 (en) * | 2008-03-25 | 2014-05-07 | Juvaris Biotherapeutics, Inc. | Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc) |
| JP6058550B2 (ja) * | 2010-12-22 | 2017-01-11 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | ウシの種における免疫応答の増強 |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| CN103721253B (zh) * | 2014-01-02 | 2015-06-10 | 青岛易邦生物工程有限公司 | 一种禽脑脊髓炎和鸡痘二联活疫苗 |
| CA2940794C (en) | 2014-02-28 | 2022-05-31 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
| US9814769B2 (en) | 2014-09-30 | 2017-11-14 | Qatar University | Vaccines against pathogenic Escherichia coli and methods of using the same |
| JP2018518511A (ja) * | 2015-06-26 | 2018-07-12 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ | 細胞質ｄｎａ監視分子の調節方法 |
| CA2993883A1 (en) * | 2015-07-31 | 2017-02-09 | Bayer Animal Health Gmbh | Enhanced immune response in porcine species |
| JP2018521108A (ja) * | 2015-07-31 | 2018-08-02 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ | 水生種における免疫応答の増強 |
| SG11201900710YA (en) | 2016-07-26 | 2019-02-27 | Bayer Animal Health Gmbh | Increased fertility in bovine species |
| SG11202004773SA (en) | 2017-12-15 | 2020-06-29 | Bayer Animal Health Gmbh | Immunostimulatory compositions |
| CN114467855A (zh) * | 2022-01-14 | 2022-05-13 | 广东海大集团股份有限公司 | 一种多病因气囊炎雏鸡模型的构建方法及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4458630A (en) * | 1982-06-22 | 1984-07-10 | The United States Of America As Represented By The Secretary Of Agriculture | Disease control in avian species by embryonal vaccination |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5427791A (en) | 1992-08-05 | 1995-06-27 | Regents Of The University Of Minnesota | Embryonal vaccine against Newcastle disease |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6048535A (en) | 1997-06-12 | 2000-04-11 | Regents Of The University Of Minnesota | Multivalent in ovo avian vaccine |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| CA2365416C (en) * | 1999-03-26 | 2011-06-14 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| US7355092B2 (en) * | 1999-12-27 | 2008-04-08 | Ronald Marquardt | Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic Escherichia coli and other pathogens |
| US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
| EP2257306B1 (en) * | 2008-03-25 | 2014-05-07 | Juvaris Biotherapeutics, Inc. | Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc) |
-
2010
- 2010-05-07 PT PT151784766T patent/PT2992899T/pt unknown
- 2010-05-07 UA UAA201114824A patent/UA106076C2/uk unknown
- 2010-05-07 CN CN201080021073.9A patent/CN102427827B/zh active Active
- 2010-05-07 NZ NZ596366A patent/NZ596366A/en not_active IP Right Cessation
- 2010-05-07 AU AU2010246652A patent/AU2010246652B2/en active Active
- 2010-05-07 US US13/320,289 patent/US20120064151A1/en not_active Abandoned
- 2010-05-07 PL PL10720350T patent/PL2429581T3/pl unknown
- 2010-05-07 SI SI201032031T patent/SI2992899T1/sl unknown
- 2010-05-07 HU HUE10720350A patent/HUE025765T2/en unknown
- 2010-05-07 PT PT107203507T patent/PT2429581E/pt unknown
- 2010-05-07 HU HUE15178476A patent/HUE051005T2/hu unknown
- 2010-05-07 RU RU2011150529/15A patent/RU2570732C9/ru active
- 2010-05-07 DK DK10720350.7T patent/DK2429581T3/en active
- 2010-05-07 KR KR1020117029865A patent/KR101966989B1/ko not_active Expired - Fee Related
- 2010-05-07 MY MYPI2011005467A patent/MY162561A/en unknown
- 2010-05-07 DK DK15178476.6T patent/DK2992899T3/da active
- 2010-05-07 ES ES15178476T patent/ES2808827T3/es active Active
- 2010-05-07 CA CA2761736A patent/CA2761736C/en active Active
- 2010-05-07 LT LTEP15178476.6T patent/LT2992899T/lt unknown
- 2010-05-07 KR KR1020177024103A patent/KR20170102379A/ko not_active Ceased
- 2010-05-07 CN CN201510317838.8A patent/CN104906573A/zh active Pending
- 2010-05-07 EP EP15178476.6A patent/EP2992899B1/en active Active
- 2010-05-07 MX MX2011011931A patent/MX336019B/es unknown
- 2010-05-07 BR BRPI1010803-3A patent/BRPI1010803A2/pt not_active Application Discontinuation
- 2010-05-07 PL PL15178476T patent/PL2992899T3/pl unknown
- 2010-05-07 SI SI201031045T patent/SI2429581T1/sl unknown
- 2010-05-07 EP EP10720350.7A patent/EP2429581B1/en active Active
- 2010-05-07 PE PE2011001938A patent/PE20120903A1/es not_active Application Discontinuation
- 2010-05-07 JP JP2012510144A patent/JP5679589B2/ja not_active Expired - Fee Related
- 2010-05-07 ES ES10720350.7T patent/ES2550181T3/es active Active
- 2010-05-07 WO PCT/EP2010/002809 patent/WO2010130374A1/en active Application Filing
- 2010-05-12 AR ARP100101647A patent/AR076767A1/es unknown
- 2010-05-12 TW TW099115052A patent/TWI555846B/zh not_active IP Right Cessation
- 2010-05-12 UY UY0001032634A patent/UY32634A/es not_active Application Discontinuation
-
2011
- 2011-10-25 IL IL215900A patent/IL215900A/en active IP Right Grant
- 2011-10-26 ZA ZA2011/07827A patent/ZA201107827B/en unknown
- 2011-11-10 CL CL2011002808A patent/CL2011002808A1/es unknown
- 2011-11-10 SV SV2011004056A patent/SV2011004056A/es unknown
- 2011-11-10 EC EC2011011448A patent/ECSP11011448A/es unknown
- 2011-11-11 CR CR20110595A patent/CR20110595A/es unknown
- 2011-11-11 NI NI201100196A patent/NI201100196A/es unknown
- 2011-11-11 CO CO11153951A patent/CO6460752A2/es not_active Application Discontinuation
-
2012
- 2012-09-06 HK HK12108738.6A patent/HK1168032A1/zh not_active IP Right Cessation
-
2015
- 2015-10-22 HR HRP20151117TT patent/HRP20151117T1/hr unknown
-
2020
- 2020-09-29 HR HRP20201554TT patent/HRP20201554T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6460752A2 (es) | Respuesta inmunitaria reforzada en especies aviares | |
| MX2019004913A (es) | Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm). | |
| CY1121789T1 (el) | Νεες ανοσοενισχυτικες συνθεσεις | |
| MX2017014538A (es) | Regimenes de cebado-refuerzo que implican la administracion de al menos un constructo de arnm. | |
| BR112016005948A2 (pt) | adjuvantes com base em óleo | |
| MX2010003642A (es) | Nanotecnologia de vacuna. | |
| MX2021002586A (es) | Dosis unitaria de vacuna contra el dengue y administracion de esta. | |
| EA201590829A1 (ru) | Новые мукозные адъюванты и системы доставки | |
| MX2017005687A (es) | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. | |
| AR080313A1 (es) | Composiciones de virus de moquillo canino (cdv) recombinante y sus usos | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| Fisher et al. | Virus-derived immunostimulatory RNA induces type I IFN-dependent antibodies and T-cell responses during vaccination | |
| MX2016000107A (es) | Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria. | |
| CO2020009043A2 (es) | Anticuerpos humanos contra hemaglutinina de influenza | |
| AR105160A1 (es) | Métodos de modulación de moléculas de vigilancia de adn citosólicas | |
| BR112015013625A2 (pt) | adjuvante de vacinação, preparação e vacinas contendo o mesmo | |
| Cheng et al. | Topical CpG oligodeoxynucleotide adjuvant enhances the adaptive immune response against influenza A infections | |
| MX367074B (es) | Inulina y formulaciones de acetato de inulina. | |
| EA201990670A1 (ru) | ВАКЦИНЫ НА ОСНОВЕ мРНК В ЛИПИДНЫХ НАНОЧАСТИЦАХ | |
| Montaner et al. | IMT504: A new and potent adjuvant for rabies vaccines permitting significant dose sparing | |
| GT201400199A (es) | Virus de la enfermedad de marek modificado y vacunas elaboradas con él | |
| ECSP22064620A (es) | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2 | |
| AR087811A1 (es) | Vacuna contra el staphylococcus aureus | |
| BR112018007870A2 (pt) | composição imunogênica, método para a preparação de uma composição imunogênica, composição farmacêutica, vacina, método para estimular uma resposta imune em um paciente | |
| WO2016018454A3 (en) | Compositions and methods employing bcl2 and bcl2 family members |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |